The role of IL-17 in obesity-associated prostate cancer progression
The role of IL-17 in obesity-associated prostate cancer progression
批准号:
10614371
负责人:
Zongbing You
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-10-01 至 2024-03-02
关键词:
AdultAmericanAmerican Cancer SocietyAnimal ModelBindingBloodBody WeightCancer EtiologyCancer PatientCessation of lifeClinicalDevelopmentDiabetes MellitusDiagnosisDiseaseGene ExpressionGenesGlycogen Synthase Kinase 3HealthHealthcareHigh Fat DietHormonesHumanHyperinsulinismIL17 geneIncidenceInflammationInflammatoryInsulinInsulin ResistanceInsulin Signaling PathwayKnock-inKnock-outKnockout MiceKnowledgeLinkMalignant NeoplasmsMalignant neoplasm of prostateMediatingModelingMolecularMusMutationNon-Insulin-Dependent Diabetes MellitusObese MiceObesityOverweightPathologicPatientsPhosphatidylinositolsPhosphorylationPhosphorylation SitePhosphotransferasesPlasmaPrevalencePreventionProstateProstate Cancer therapyProteinsReportingResearchRiskRoleSignal PathwaySignal TransductionSpecimenSurveysTestingThinnessUbiquitinationVeteranscancer diagnosiscastration resistant prostate cancerclinically significantcytokinediabeticdiet-induced obesityepidemiology studyglycogen synthase kinase 3 betahigh riskinhibitorinsulin signalingmenmortalitymulticatalytic endopeptidase complexmutantnovelobese personprostate cancer progressionprostate cancer riskreceptorresponsetumor
中文摘要
约35.5%的美国男性肥胖,肥胖与前列腺高分级呈正相关
癌症、去势抵抗性前列腺癌和前列腺癌特异性死亡率。肥胖症的发病
与前列腺癌患者中50%的病理进展风险增加相关,
监视然而,肥胖和前列腺之间联系的分子机制
癌症进展仍然是有待填补的重大知识空白。据了解,肥胖的人往往
发展为2型糖尿病(T2 D),血液中胰岛素和炎性细胞因子水平升高,
白细胞介素-17(IL-17)。我们之前已经证明IL-17促进了初治性乳腺癌的发展,
和去势抵抗性前列腺癌。我们的初步研究发现前列腺癌
在高脂饮食诱导的肥胖Pten基因敲除小鼠中,
瘦的Pten缺失小鼠。我们已经证明,胰岛素通过以下途径增强IL-17诱导的基因表达:
抑制糖原合成酶激酶3(GSK 3)。此外,我们最初发现GSK 3结合并
使IL-17受体A(IL-17 RA)在残基T780处磷酸化,导致泛素化和蛋白酶体介导的
IL-17 RA的降解。在肥胖小鼠中,高胰岛素血症激活了磷脂酰肌醇3-激酶(PI 3 K)/Akt,
在S21磷酸化GSK 3 α,在S9磷酸化GSK 3 β,从而抑制GSK 3活性;随后,IL-17 RA
GSK 3的磷酸化减少,导致IL-17 RA蛋白水平增加,随后增强
IL-17信号传导和多种IL-17下游基因的表达增加。这些结果表明,IL-
17信号和胰岛素信号通过GSK 3的串扰,这是一种新的机制,肥胖驱动
前列腺癌进展。基于这些发现,我们提出了一个中心假设,即GSK 3是
一种IL-17信号传导的内在抑制剂,在患有T2 D的肥胖症中,高水平的胰岛素增强IL-17介导的
通过抑制GSK 3活性,从而促进前列腺癌进展。我们建议
通过实现以下三个具体目标来测试我们的中心假设:目标1)确定GSK 3的作用
在Pten基因缺失的肥胖小鼠中调节IL-17的促肿瘤功能。我们将使用两种动物模型:a)我们将
用野生型IL-17 ra建立Gsk 3 α;Pten和Gsk 3 β;Pten双敲除小鼠;我们期望发现
在IL-17 RA被GSK 3磷酸化中,IL-17 RA降解减少,IL-17介导的IL-17 RA磷酸化增加。
小鼠前列腺炎症,导致前列腺癌发病率增加; B)我们将产生IL-17 ra
T779 A敲入突变体(IL-17 raKI/KI)小鼠,其将不响应GSK 3介导的IL-17 RA磷酸化,
从而允许评估GSK 3的IL-17非依赖性功能;小鼠T779与人T780同源
IL-17 RA;我们预计与Gsk 3 α;Pten相比,
和Gsk 3 β;Pten双敲除小鼠与具有IL-17 RA T779 A突变的Gsk 3野生型Pten缺失小鼠。目的
2)定义GSK 3抑制IL-17信号传导的分子机制。我们将确定IL-17 RA是否
在T780处被GSK 3磷酸化需要引发的磷酸化,并且如果存在其他GSK 3
IL-17 RA上的磷酸化位点。目的3)评估GSK 3/IL-17状态与前列腺增生的关系
肥胖/糖尿病男性的癌症。我们将评估500例前列腺癌标本中的GSK 3/IL-17状态,
正常体重、超重和肥胖的患者,伴或不伴T2 D;我们将评估
GSK 3/IL-17状态与临床变量之间的关系。成功完成拟议的研究将
提供了肥胖如何驱动前列腺癌进展的新分子机制,这将显着
促进知识和揭示新的目标,在预防和治疗前列腺癌。
英文摘要
About 35.5% American men are obese and obesity has been positively associated with high-grade prostate
cancer, castration-resistant prostate cancer, and prostate cancer-specific mortality. Obesity has been
associated with a 50% increased risk of pathological progression in prostate cancer patients under active
surveillance. However, the molecular mechanisms underlying the association between obesity and prostate
cancer progression remain as a significant knowledge gap to be filled. It is known that obese people often
develop type 2 diabetes (T2D) with increased blood levels of insulin and inflammatory cytokines such as
interleukin-17 (IL-17). We have previously demonstrated that IL-17 promotes development of hormone-naïve
and castration-resistant prostate cancer in Pten-null mice. Our preliminary studies found that prostate cancer
formation rate was increased by approximately 82% in high-fat diet-induced obese Pten-null mice compared to
lean Pten-null mice. We have demonstrated that insulin enhances IL-17-induced gene expression through
inhibition of glycogen synthase kinase 3 (GSK3). Moreover, we have originally found that GSK3 binds to and
phosphorylates IL-17 receptor A (IL-17RA) at residue T780, leading to ubiquitination and proteasome-mediated
degradation of IL-17RA. In obese mice, hyperinsulinemia activated phosphoinositide 3-kinase (PI3K)/Akt to
phosphorylate GSK3α at S21 and GSK3β at S9, thus inhibiting GSK3 activity; subsequently, IL-17RA
phosphorylation by GSK3 is reduced, resulting in increased levels of IL-17RA protein, followed by enhanced
IL-17 signaling and increased expression of multiple IL-17 downstream genes. These findings suggest that IL-
17 signaling and insulin signaling crosstalk via GSK3, which is a novel mechanism by which obesity drives
prostate cancer progression. Based on these findings, we have formulated a central hypothesis that GSK3 is
an intrinsic inhibitor of IL-17 signaling, and in obesity with T2D, high levels of insulin enhance IL-17-mediated
responses through inhibiting GSK3 activities, thereby promoting prostate cancer progression. We propose to
test our central hypothesis through achieving the following three specific aims: Aim 1) Determine GSK3’s role
in regulating IL-17’s pro-tumor function in Pten-null obese mice. We will use two animal models: a) we will
create Gsk3α;Pten and Gsk3β;Pten double knockout mice with wild-type IL-17ra; we expect to find a decrease
in IL-17RA phosphorylation by GSK3, a decrease in IL-17RA degradation, and an increase in IL-17-mediated
inflammation in mouse prostate, resulting in an increase in prostate cancer incidence; b) we will create IL-17ra
T779A knockin mutant (IL-17raKI/KI) mice that will not respond to GSK3-mediated phosphorylation of IL-17RA,
thus allowing assessment of IL-17-independent functions of GSK3; mouse T779 is homologous to human T780
on IL-17RA; we expect to find no significant differences in prostate cancer formation comparing Gsk3α;Pten
and Gsk3β;Pten double knockout mice with Gsk3 wild-type Pten-null mice with IL-17RA T779A mutation. Aim
2) Define the molecular mechanisms by which GSK3 inhibits IL-17 signaling. We will determine if IL-17RA
phosphorylation at T780 by GSK3 requires a primed phosphorylation and if there are other GSK3
phosphorylation sites on IL-17RA. Aim 3) Assess the association between GSK3/IL-17 status and prostate
cancer in obese/diabetic men. We will assess GSK3/IL-17 status in 500 prostate cancer specimens from
patients with normal body weight, overweight, and obesity, with or without T2D; we will assess the associations
between GSK3/IL-17 status and the clinical variables. Successful completion of the proposed studies will
provide novel molecular mechanisms of how obesity drives prostate cancer progression, which will significantly
advance the knowledge and reveal new targets in the prevention and treatment of prostate cancer.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/biomedicines10081976
发表时间:
2022-08-15
期刊:
Biomedicines
影响因子:
4.7
作者:
[]
通讯作者:
Intra-arterial injection to create bone metastasis of prostate cancer in mice.
动脉内注射在小鼠体内产生前列腺癌骨转移。
DOI:
--
发表时间:
2020
期刊:
American journal of clinical and experimental urology
影响因子:
1.2
作者:
[Zhong,Lin, Miller,HaiyanD, Zhang,Yongfeng, Jin,Ben, Ge,Dongxia, You,Zongbing]
通讯作者:
You,Zongbing
PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors.
PD-L1(而不是 PD-1)状态与人类原发性前列腺肿瘤的临床特征相关。
DOI:
--
发表时间:
2019
期刊:
American journal of clinical and experimental urology
影响因子:
1.2
作者:
[Xian,Peng, Ge,Dongxia, Wu,VictorJ, Patel,Avi, Tang,WendellW, Wu,Xiaocheng, Zhang,Kun, Li,Li, You,Zongbing]
通讯作者:
You,Zongbing
Genome and transcriptome profiling of FBXW family in human prostate cancer.
人类前列腺癌 FBXW 家族的基因组和转录组分析。
DOI:
--
发表时间:
2020
期刊:
American journal of clinical and experimental urology
影响因子:
1.2
作者:
[Lan,Ruoxin, Jin,Ben, Liu,Yao-Zhong, Zhang,Kun, Niu,Tianhua, You,Zongbing]
通讯作者:
You,Zongbing
Novel discoveries in urology: big data to microbiome - highlights of the society for basic urologic research 2019 annual meeting.
泌尿外科新发现:大数据到微生物组——泌尿基础研究学会2019年年会亮点
DOI:
--
发表时间:
2020
期刊:
American journal of clinical and experimental urology
影响因子:
1.2
作者:
[Jin,Ben, Prins,GailS, Adam,Rosalyn, Yu,Jindan, Sfanos,KarenS, Li,Benyi, Hu,Chang-Deng, Dong,Yan, You,Zongbing]
通讯作者:
You,Zongbing
共 8 条
Society for Basic Urologic Research 2019 Annual Meeting "NOVEL DISCOVERIES IN UROLOGY: BIG DATA TO MICROBIOME"
-
批准号:9895262
-
项目类别:
-
资助金额:$0.4万
-
财政年份:2019
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in obesity-associated prostate cancer progression
-
批准号:10047293
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in obesity-associated prostate cancer progression
-
批准号:10292940
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in obesity-associated prostate cancer progression
-
批准号:9558387
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in prostate cancer
-
批准号:8858592
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2013
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in prostate cancer
-
批准号:9273485
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2013
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in prostate cancer
-
批准号:8675806
-
项目类别:
-
资助金额:$30.29万
-
财政年份:2013
-
负责人:Zongbing You
-
依托单位:
The role of IL-17 in prostate cancer
-
批准号:8475822
-
项目类别:
-
资助金额:$31.23万
-
财政年份:2013
-
负责人:Zongbing You
-
依托单位:
THE ROLE OF CYTOKINE RECEPTOR INTERLEUKIN-17RC IN INITIATION OF PROSTATE CANCER
-
批准号:8360724
-
项目类别:
-
资助金额:$27.35万
-
财政年份:2004
-
负责人:Zongbing You
-
依托单位:
THE ROLE OF CYTOKINE RECEPTOR INTERLEUKIN-17RC IN INITIATION OF PROSTATE CANCER
-
批准号:8168373
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2004
-
负责人:Zongbing You
-
依托单位:
海外基金